
Hospira, Inc., a subsidiary of Pfizer, is voluntarily recalling specific lots of Sodium Bicarbonate Injections (4.2% and 8.4%) and Atropine Sulfate Injection due to potential glass particulate matter. The recall, initiated after product inspection, poses a risk of serious adverse events for patients, including vein inflammation and life-threatening blood clot events. Healthcare professionals are urged to visually inspect the products for particulate matter before administration. As of now, Hospira, Inc. has not received reports of adverse events related to this issue. The impacted products were distributed nationwide from March 14, 2023, through June 29, 2023.
Like
Save
Share